Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense, Inc Director Ronald B. Herberman Dies at 72

June 3, 2013 - Pittsburgh, Pennsylvania

Dr. Ronald B. Herberman died unexpectedly on June 1, 2013 at the age of 72. Dr. Herberman was the founding director of the University of Pittsburgh Cancer Institute and a founding director of Celsense, Inc. Dr. Herberman was an internationally recognized tumor immunologist who has made major discoveries in his field, most notably the initial descriptions of natural killer (NK) cells, and he has fostered the application of this information to novel approaches to cancer therapy.

In 2009, Dr. Herberman relocated to Potomac, Maryland, commencing a new career in the pharmaceutical industry. Most recently, he served as senior vice president and chief medical officer at TNI BioTech, Inc. He is survived by his wife, Harriett, and his children Holly and Steven, and three grandchildren.

“Ron helped us launch the company in 2005, was a loyal friend, and good counselor. He will be missed,” said Charlie O’Hanlon, President and CEO of Celsense.

About Celsense
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com